Skip to main content

Vistagen Therapeutics, Inc.

VTGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001411685

No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Vistagen Therapeutics, Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of VTGN: Q3 2024 compared with Q4 2024
MeasureQ3 2024Q4 2024Change
Holders4754+7
Shares15.3M15.5M+260.1K (+1.7%)
Value$45.3M$44.9M−$422.3K (−0.9%)

New holders (15)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to VTGN in Q4 2024
InstitutionSharesValue% of portfolio
Diadema Partners LP442,520$1.31M1.47%
Almitas Capital LLC254,655$751.2K0.16%
Persistent Asset Partners Ltd121,651$351.6K0.30%
Group One Trading, L.P.97,727$288.3K0.01%
Ikarian Capital, LLC77,616$229.0K0.07%
Landscape Capital Management, L.L.C.41,804$123.3K0.01%
Prosperity Wealth Management, Inc.29,250$86.3K0.04%
Boothbay Fund Management, LLC22,415$66.1K0.00%
Man Group plc18,338$54.1K0.00%
Two Sigma Advisers, LP12,032$35.5K0.00%
R Squared Ltd8,610$25.4K0.02%
Performa Ltd (US), LLC1,000$2.95K0.00%
MAI Capital Management609$1.80K0.00%
BNP Paribas Arbitrage, SA473$1.40K0.00%
SBI Securities Co., Ltd.286$8440.00%

Sold out (8)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.

Institutions that sold out of VTGN in Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
BVF Inc2,000,000$6.02M
Great Point Partners LLC674,075$2.03M
Citadel Advisors LLC321,885$968.9K
Valence8 US LP34,376$103.5K
Virtu Financial LLC20,210$61.0K
Jane Street Group, LLC19,659$59.2K
Farther Finance Advisors, LLC81$244
FMR LLC25$75